In the midst of June’s peak wedding season, Highridge Medical LLC called it splitsville – selling its bone healing division to Avista Healthcare Partners. The latest separation continues the sundering of what Zimmer Biomet Holdings Inc. so carefully joined together a decade ago.
Researchers at ETH Zürich developed Menstruai, a device that detects in menstruation blood biomarkers associated with certain diseases. Menstruai uses a sensor built into a sanitary pad and changes color if certain biomarkers are present. The first of its kind technology has the potential to enable the early detection of diseases and transform women’s health care.
The U.S. FDA’s Center for Devices and Radiological Health is recovering from a guidance drought that spanned several months in the first part of calendar year 2025, starting with a guidance on the Q-sub process.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Autonomix, Elekta, Fujirebio, Fluxus, Healthverity, Linear Diagnostics, Medeloop, MGI Tech, Natera, Owens & Minor, Rotech.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Avicenna, Foldax, Medtronic, Merz Pharma, Nano-X.
BioWorld covers the Trump administration’s latest policy decisions and actions affecting the life sciences sector, as well as their impacts across the globe.
Researchers from the University of Arizona have unveiled that coordinated Y chromosome loss in both cancer cells and immune cells may explain the worse prognosis in people with this alteration. The loss of the Y chromosome is one of the most frequent somatic mutations in men, particularly with advancing age.
RSS
